Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $14.34 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $14.34B | +1.0% |
| 2024 | $14.20B | +8.3% |
| 2023 | $13.12B | +7.8% |
| 2022 | $12.17B | -24.3% |
| 2021 | $16.07B | +89.1% |
| 2020 | $8.50B | +29.6% |
| 2019 | $6.56B | +27.4% |
| 2018 | $5.15B | -12.4% |
| 2017 | $5.87B | +20.8% |
| 2016 | $4.86B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.75B | +0.9% | +2.1% |
| June 30, 2025 | $3.68B | +3.6% | +21.4% |
| March 31, 2025 | $3.03B | -3.7% | -18.6% |
| September 30, 2024 | $3.72B | +10.6% | +4.9% |
| June 30, 2024 | $3.55B | +12.3% | +12.8% |
| March 31, 2024 | $3.15B | -0.5% | -6.5% |
| September 30, 2023 | $3.36B | +14.5% | +6.5% |
| June 30, 2023 | $3.16B | +10.5% | -0.1% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +1.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, REGENERON PHARMACEUTICALS, INC.’s revenue (asc 606) has grown by 195.1% (from $4.86 billion to $14.34 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: